Sanofi’s Dupixent Benefits In Chronic Spontaneous Urticaria Add To Strong Second Quarter

EPS Guidance For 2021 Updated

 
• By John Davis
  
sanofi in france
• Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business